Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 16/20 | 0.64 |
| ▸ | THRB | P10828 | 16/20 | 0.64 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.64 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.58 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.55 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ASPH | Q12797 | 1/20 | 0.52 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31028948 | 1.00 | THRA (0.64) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL1509116 | 0.92 | THRA (0.75) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL30004356 | 0.92 | THRA (0.75) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL28239651 | 0.89 | THRA (0.64) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL30004549 | 0.88 | THRA (0.69) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL1508977 | 0.88 | THRA (0.69) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL4081493 | 0.88 | THRA (0.56) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL4070358 | 0.88 | THRA (0.56) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL28567789 | 0.87 | THRA (0.84) | THRATHRBEGLN1EGLN2BBOX1 | |
| SCHEMBL27615536 | 0.85 | THRA (0.57) | THRATHRBEGLN1EGLN2BBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101664551-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-14 | — | — | CN | claimed |
| US-8202834-B2 | Fat regulation | FIBROGEN, INC. (US) | 2012-06-19 | — | — | US | claimed |
| US-8124582-B2 | stabilizing alpha subunit of hypoxia inducible factor protein (HIF alpha ), thereby regulating glucose metabolism; preventing or treating hyperglycemia, obesity, hypertension, hyperlipidemia, nephropathy, neuropathy, retinopathy, impaired glucose tolerance, atherosclerosis, and vascular disease | FIBROGEN, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20100168152-A1 | Fat regulation | FIBROGEN, INC. (US) | 2010-07-01 | — | — | US | claimed |
| US-7618940-B2 | Fat regulation | FIBROGEN, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20060258702-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. (US) | 2006-11-16 | — | — | US | claimed |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | WYETH (US) | 2006-09-28 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| WO-2006099610-A2 | METHODS OF IDENTIFYING THERAPEUTIC TARGETS FOR THE TREATMENT OF VULVOVAGINAL ATROPHY | WYETH (US) | 2006-09-21 | — | — | WO | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | FIBROGEN, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11969417-B2 | Topical formulation for use in alopecia | TOMORROWLABS GMBH (AT) | 2024-04-30 | — | — | US | disclosed |
| EP-3917525-B1 | NEW TOPICAL FORMULATION FOR USE IN ALOPECIA | TOMORROWLABS GMBH (AT) | 2024-02-28 | — | — | EP | disclosed |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | FIBROGEN, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2004052284-A2 | TREATMENT OF DIABETES | FIBROGEN, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004052285-A2 | FAT REGULATION | FIBROGEN, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN, INC. | 2003-09-18 | — | — | US | disclosed |
| WO-2003049686-A2 | STABILIZATION OF HYPOXIA INDUCIBLE FACTOR (HIF) ALPHA | FIBROGEN, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176317-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | THRA 1730/4885THRB 2049/4885EGLN1 7/4885 |
| US-20060216295-A1 | Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy | DNASE1L3, ANXA4, SERPINA6 | THRA 3799/4885THRB 3714/4885EGLN1 863/4885 |
| US-11680048-B2 | Enhanced erythropoiesis and iron metabolism | EPOR, HAMP, TFRC | THRA 1955/4885THRB 1347/4885EGLN1 24/4885 |
| US-20060258702-A1 | Stabilization of hypoxia inducible factor (HIF) alpha | HIF1A, HIF1AN, EGLN2 | THRA 1730/4885THRB 2049/4885EGLN1 7/4885 |
| US-20240182424-A1 | ENHANCED ERYTHROPOIESIS AND IRON METABOLISM | EPOR, HAMP, TFRC | THRA 1955/4885THRB 1347/4885EGLN1 24/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | THRA 1089/4885THRB 1815/4885EGLN1 16/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | THRA 822/4885THRB 1449/4885EGLN1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.